A new drug used to treat metastatic melanoma patients who have the genetic mutation known as BRAFV600E demonstrated significant tumor shrinkage in the majority of patients during a clinical trial.
Data from the Phase I trial of the drug PLX4032, developed by Plexxikon Inc. and Roche Pharmaceuticals, showed that nearly all patients with the mutation who were treated with the drug showed some response and 81 percent of patients had tumor shrinkage of at least 30 percent. The data were published in the New England Journal of Medicine.
Igor Puzanov, M.D., assistant professor of Medicine, and Jeffrey Sosman, M.D., professor of Medicine, Vanderbilt-Ingram Cancer Center, are among the principal investigators on the study. Keith Flaherty, M.D., Massachusetts General Hospital Cancer Center of Harvard University, is lead author.